SMAD2 and keloid: Aberrant activation of TGFß signaling has also been implicated in scleroderma fibrosis [20], [21], [71], [72] and in keloid, a fibrotic disease characterized by abnormal accumulation of ECM in the dermis via reduction in TGFß/p-SMAD-2 [73].